CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB
D.L. No. 1800-OSP, 1804-B I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com

Date: November 06, 2024

To
The BSE Limited
Department of Corporate Services,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: 539997

Subject : Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 – Kwality Pharma received the approval for Leuprorelin Acetate for injectable suspension as a site variation from Greece

Kwality Pharmaceuticals Limited ('KPL') has successfully filed and got the approval for Leuprorelin Acetate 11.25 mg vial powder and solvent for injectable suspension as a site variation in Greece, marking our entry into the European Markets.

Kwality Pharma will supply the first three validation batches in December and after complete Quality Control Analysis, will start regular supplies from January 2025 onwards.

This strategic CDMO arrangement is projected to generate around USD 3 million of yearly sales, with distribution set to begin in the 4th Quarter of this fiscal year. Furthermore, we have plans to add remaining strengths of the same in the product portfolio with the same buyer as well.

This marks a pivotal step in our company strategy to introduce our products in highly regulated markets.

The above is for your information and dissemination to the stakeholders.

Thanking You,

For Kwality Pharmaceuticals Limited

Ramesh Arora
Managing Director
DIN: 00462656